Shopping Cart 0
Cart Subtotal
USD 0

Immunomedics Inc (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technologies namely, ADC Linker technology and Dock-And-Lock platform. Its lead product candidate is Sacituzumab govitecan (IMMU-132) in Phase II development stage received breakthrough therapy designation from the US FDA for the treatment of patients with metastatic triple-negative breast cancer and metastatic solid cancers. Immunomedics' other lead product candidates include Labetuzumab Govitecan (IMMU-130) and Epratuzumab. It also has other product candidates that target solid tumors, hematologic malignancies and other diseases, in various stages of clinical and pre-clinical development. The company also manufactures and commercializes diagnostic imaging product named, LeukoScan. Immunomedics is headquartered in Morris Plains, New Jersey, the US.

Immunomedics Inc (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Immunomedics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Immunomedics Enters into Research Agreement with Yale Cancer Center 12

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13

Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14

Immunomedics Expands Clinical Collaboration with AstraZeneca 15

Clovis Oncology Enters into Agreement with Immunomedics 16

Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17

Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18

Equity Offering 19

Immunomedics Raises USD276 Million in Public Offering of Shares 19

Immunomedics to Raise USD75 Million in Private Placement of Shares 21

Immunomedics Plans to Raise Funds through Public Offering of Shares 23

Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24

Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25

Immunomedics Completes Public Offering Of Shares For USD 30.2 Million 27

Immunomedics Completes Public Offering Of Common Stock For USD 16 Million 29

Debt Offering 30

Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30

Asset Transactions 32

Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32

Acquisition 33

Seattle Genetics Acquires 2.8% Stake in Immunomedics 33

Immunomedics Inc-Key Competitors 35

Immunomedics Inc-Key Employees 36

Immunomedics Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Nov 07, 2018: Immunomedics announces first quarter fiscal 2019 results and provides corporate update 38

Aug 23, 2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update 40

May 09, 2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update 42

Feb 08, 2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update 44

Nov 09, 2017: Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update 46

Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 48

May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 50

Feb 09, 2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments 52

Corporate Communications 54

Apr 09, 2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer 54

Jan 09, 2017: Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 55

Legal and Regulatory 56

Feb 21, 2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws 56

Government and Public Interest 57

May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 57

Product News 60

11/09/2017: Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth 60

02/23/2017: Immunomedics Announces Company's Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies 62

02/17/2017: Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer 63

01/26/2017: venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics 64

01/18/2017: Immunomedics Announces New Data for IMMU-132 at Investor R&D Day 65

Product Approvals 68

Aug 16, 2017: Immunomedics provides update on IMMU-132 68

Clinical Trials 69

Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 69

Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 70

Sep 11, 2017: Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer 71

Aug 21, 2017: Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer 72

Jul 10, 2017: Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics' Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers 73

Apr 05, 2017: Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients with Metastatic Small-Cell Lung Cancer who are Sensitive or Resistant to First-Line Chemotherapy 75

Apr 04, 2017: Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan 76

Apr 04, 2017: Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression 77

Mar 15, 2017: Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer 78

Jan 09, 2017: Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors 80

Appendix 82

Methodology 82

About GlobalData 82

Contact Us 82

Disclaimer 82


List Of Figure

List of Figures

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Immunomedics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Immunomedics Enters into Research Agreement with Yale Cancer Center 12

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13

Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14

Immunomedics Expands Clinical Collaboration with AstraZeneca 15

Clovis Oncology Enters into Agreement with Immunomedics 16

Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17

Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18

Immunomedics Raises USD276 Million in Public Offering of Shares 19

Immunomedics to Raise USD75 Million in Private Placement of Shares 21

Immunomedics Plans to Raise Funds through Public Offering of Shares 23

Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24

Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25

Immunomedics Completes Public Offering Of Shares For USD 30.2 Million 27

Immunomedics Completes Public Offering Of Common Stock For USD 16 Million 29

Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30

Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32

Seattle Genetics Acquires 2.8% Stake in Immunomedics 33

Immunomedics Inc, Key Competitors 35

Immunomedics Inc, Key Employees 36

Immunomedics Inc, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Immunomedics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technologies namely, ADC Linker technology and Dock-And-Lock platform. Its lead product candidate is Sacituzumab govitecan (IMMU-132) in Phase II development stage received breakthrough therapy designation from the US FDA for the treatment of patients with metastatic triple-negative breast cancer and metastatic solid cancers. Immunomedics' other lead product candidates include Labetuzumab Govitecan (IMMU-130) and Epratuzumab. It also has other product candidates that target solid tumors, hematologic malignancies and other diseases, in various stages of clinical and pre-clinical development. The company also manufactures and commercializes diagnostic imaging product named, LeukoScan. Immunomedics is headquartered in Morris Plains, New Jersey, the US.

Immunomedics Inc (IMMU)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Immunomedics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Immunomedics Enters into Research Agreement with Yale Cancer Center 12

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13

Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14

Immunomedics Expands Clinical Collaboration with AstraZeneca 15

Clovis Oncology Enters into Agreement with Immunomedics 16

Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17

Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18

Equity Offering 19

Immunomedics Raises USD276 Million in Public Offering of Shares 19

Immunomedics to Raise USD75 Million in Private Placement of Shares 21

Immunomedics Plans to Raise Funds through Public Offering of Shares 23

Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24

Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25

Immunomedics Completes Public Offering Of Shares For USD 30.2 Million 27

Immunomedics Completes Public Offering Of Common Stock For USD 16 Million 29

Debt Offering 30

Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30

Asset Transactions 32

Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32

Acquisition 33

Seattle Genetics Acquires 2.8% Stake in Immunomedics 33

Immunomedics Inc-Key Competitors 35

Immunomedics Inc-Key Employees 36

Immunomedics Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Nov 07, 2018: Immunomedics announces first quarter fiscal 2019 results and provides corporate update 38

Aug 23, 2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update 40

May 09, 2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update 42

Feb 08, 2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update 44

Nov 09, 2017: Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update 46

Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 48

May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 50

Feb 09, 2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments 52

Corporate Communications 54

Apr 09, 2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer 54

Jan 09, 2017: Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 55

Legal and Regulatory 56

Feb 21, 2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws 56

Government and Public Interest 57

May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 57

Product News 60

11/09/2017: Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth 60

02/23/2017: Immunomedics Announces Company's Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies 62

02/17/2017: Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer 63

01/26/2017: venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics 64

01/18/2017: Immunomedics Announces New Data for IMMU-132 at Investor R&D Day 65

Product Approvals 68

Aug 16, 2017: Immunomedics provides update on IMMU-132 68

Clinical Trials 69

Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 69

Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 70

Sep 11, 2017: Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer 71

Aug 21, 2017: Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer 72

Jul 10, 2017: Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics' Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers 73

Apr 05, 2017: Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients with Metastatic Small-Cell Lung Cancer who are Sensitive or Resistant to First-Line Chemotherapy 75

Apr 04, 2017: Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan 76

Apr 04, 2017: Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression 77

Mar 15, 2017: Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer 78

Jan 09, 2017: Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors 80

Appendix 82

Methodology 82

About GlobalData 82

Contact Us 82

Disclaimer 82


List Of Figure

List of Figures

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Immunomedics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immunomedics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Immunomedics Enters into Research Agreement with Yale Cancer Center 12

Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13

Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14

Immunomedics Expands Clinical Collaboration with AstraZeneca 15

Clovis Oncology Enters into Agreement with Immunomedics 16

Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17

Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18

Immunomedics Raises USD276 Million in Public Offering of Shares 19

Immunomedics to Raise USD75 Million in Private Placement of Shares 21

Immunomedics Plans to Raise Funds through Public Offering of Shares 23

Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24

Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25

Immunomedics Completes Public Offering Of Shares For USD 30.2 Million 27

Immunomedics Completes Public Offering Of Common Stock For USD 16 Million 29

Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30

Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32

Seattle Genetics Acquires 2.8% Stake in Immunomedics 33

Immunomedics Inc, Key Competitors 35

Immunomedics Inc, Key Employees 36

Immunomedics Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Immunomedics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.